...
首页> 外文期刊>Retina >ROLE OF INTRAVITREAL BEVACIZUMAB IN EALES DISEASE WITH DENSE VITREOUS HEMORRHAGE A Prospective Randomized Control Study
【24h】

ROLE OF INTRAVITREAL BEVACIZUMAB IN EALES DISEASE WITH DENSE VITREOUS HEMORRHAGE A Prospective Randomized Control Study

机译:葡萄球菌内腔注射贝伐珠单抗在密集型玻璃体出血中的作用前瞻性随机对照研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: To investigate the role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage.Methods: This is a prospective randomized control trial. Twenty eyes of 20 patients with dense vitreous hemorrhage because of Eales disease were randomly distributed in Group 1 (n = 10) and Group 2 (n = 10). Group 1 eyes received intravitreal injection of bevacizumab (1.25 mg/0.05 ml_) every 4 weeks, and Group 2 eyes were observed. Patients of both groups were followed-up every 2 weeks. Vitrectomy was performed in case of nonresolving vitreous hemorrhage Grade 2 or more after 3 months of enrollment or immediately if retinal detachment was detected. Intraoperative difficulties while performing surgery and excessive bleeding were noted. The primary outcome measures were reduction in the grade of vitreous hemorrhage and the need for vitrectomy.Results: Only 1 eye from Group 1 and 2 eyes from Group 2 showed decrease in vitreous hemorrhage to Grade 2 (P = 0.531, 95% confidence interval). But all three eyes required vitrectomy because of persisting poor vision. Postoperative mean vision +- SD in Group 1 was 1.2 +- 0.57 in logarithm of the minimum angle of resolution units, and in Group 2, it was 0.78 +- 0.41 in logarithm of the minimum angle of resolution units (P = 0.086, 95% confidence interval). Three eyes (30%) in Group 1 had tractional retinal detachment after a single bevacizumab injection, while none of the Group 2 eyes had tractional retinal detachment (P = 0.060, 95% confidence interval). Vitrectomy was performed in all three eyes and had poor visual outcome after surgery. No intraoperative difficulties were noted in either group.Conclusion: The authors' study showed that repeated intravitreal bevacizumab in patients with Eales disease with dense vitreous hemorrhage may not hasten the resolution of vitreous hemorrhage or reduce the need for vitrectomy. Moreover, tractional retinal detachment may be a serious complication of therapy and hence should be c...
机译:目的:探讨玻璃体内贝伐单抗在Eales病合并玻璃体大出血中的作用。方法:这是一项前瞻性随机对照试验。 20眼因Eales病而致玻璃体出血的患者中有20只眼随机分配在第1组(n = 10)和第2组(n = 10)中。第1组眼睛每4周接受玻璃体内注射贝伐单抗(1.25 mg / 0.05 mL)注射,观察第2组眼睛。两组患者每2周进行一次随访。入选3个月后未解决2级或以上的玻璃体出血,或如果检测到视网膜脱离,应立即行玻璃体切除术。注意到进行手术时的术中困难和大量出血。主要的结局指标是减少玻璃体出血的等级和需要进行玻璃体切割的结果。结果:第1组的1只眼和第2组的2只眼显示玻璃体出血降至2级(P = 0.531,置信区间为95%) 。但由于视力持续不佳,三只眼睛都需要进行玻璃体切除术。第一组的术后平均视力±SD为最小分辨率单位的对数为1.2±-0.57,在第2组,最小分辨率为对数单位的对数为0.78±0.41(P = 0.086,95 %置信区间)。第一组的三只眼(30%)在单次贝伐单抗注射后出现了视网膜脱离,而第二组的一只眼都没有视网膜脱离(P = 0.060,95%置信区间)。三只眼睛均进行了玻璃体切除术,术后视力不佳。结论:作者的研究表明,玻璃体出血严重的Eales病患者反复进行玻璃体内贝伐单抗可能无法加快玻璃体出血的缓解或减少玻璃体切除的需要。此外,牵引性视网膜脱离可能是治疗的严重并发症,因此应予以治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号